Acetonitrile

Acetonitrile

SCHEMBL169615

CC#N.CC#N.CC#N.N#CCCO

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 3/20 0.38
LOX P28300 1/20 0.35
LOXL3 P58215 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
CYP3A4 P08684 1/20 0.35
NLRP3 Q96P20 1/20 0.33
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetonitrile SCHEMBL368167 1.00 ALDH1A1 (0.44) ALDH1A1TDP1TSHRLOXLOXL3
Acetonitrile SCHEMBL368969 1.00
Acetonitrile SCHEMBL15232266 1.00 ALDH1A1 (0.44) ALDH1A1TDP1TSHRLOXLOXL3
Methyl Alcohol SCHEMBL16240074 0.90 ALDH1A1 (0.47) ALDH1A1TDP1TSHRLOXLOXL3
Methyl Alcohol SCHEMBL7165044 0.90
Water SCHEMBL2192190 0.89
SCHEMBL25008 0.89
SCHEMBL30498455 0.89
SCHEMBL29172255 0.86
SCHEMBL28283743 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853437-B2 Anti-inflammatory compounds THE UNIVERSITY OF TOKYO (JP) 2014-10-07 US claimed
US-20120059061-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS THE UNIVERSITY OF TOKYO (JP) 2012-03-08 US claimed
EP-2415748-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS The University of Tokyo (JP) 2012-02-08 EP claimed
US-9238634-B2 Anti-inflammatory metabolite derived from omega-3-type fatty acid THE UNIVERSITY OF TOKYO (JP) 2016-01-19 US disclosed
US-8895732-B2 Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives MERCK PATENT GMBH (DE) 2014-11-25 US disclosed
US-8853437-B2 Anti-inflammatory compounds THE UNIVERSITY OF TOKYO (JP) 2014-10-07 US disclosed
US-20130274327-A1 NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID THE UNIVERSITY OF TOKYO (JP) 2013-10-17 US disclosed
EP-2607358-A1 NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID The University of Tokyo (JP) 2013-06-26 EP disclosed
US-20120059061-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS THE UNIVERSITY OF TOKYO (JP) 2012-03-08 US disclosed
EP-2415748-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS The University of Tokyo (JP) 2012-02-08 EP disclosed
US-20120016121-A1 Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-01-19 US disclosed
EP-0064487-A1 New substituted 3-(parasubstituted)phenoxy-1-alkylamino-propanol-2-s, as well as process for their preparation, pharmaceutical preparations containing same, and method for treating cardiac failure Aktiebolaget Hässle (SE) 1982-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016121-A1 Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives RER1, ABCB11, SLC67A1 ALDH1A1 43/4885TDP1 2603/4885TSHR 791/4885
US-20120059061-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS ALOX15, ALOX15B, ALOX12 ALDH1A1 1074/4885TDP1 3367/4885TSHR 4542/4885
US-20130274327-A1 NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID PTGES3, ALOX5, ALOX15 ALDH1A1 895/4885TDP1 4739/4885TSHR 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.